Bristol Myers Squibb Company (NYSE:BMY) Shares Purchased by Concurrent Investment Advisors LLC

Concurrent Investment Advisors LLC lifted its stake in Bristol Myers Squibb Company (NYSE:BMY - Free Report) by 117.3% during the 1st quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 76,874 shares of the biopharmaceutical company's stock after buying an additional 41,504 shares during the period. Concurrent Investment Advisors LLC's holdings in Bristol Myers Squibb were worth $4,689,000 as of its most recent SEC filing.

Several other large investors have also recently modified their holdings of the stock. King Wealth Management Group lifted its stake in shares of Bristol Myers Squibb by 2.6% in the 4th quarter. King Wealth Management Group now owns 7,294 shares of the biopharmaceutical company's stock worth $413,000 after acquiring an additional 182 shares during the period. Thoroughbred Financial Services LLC lifted its stake in shares of Bristol Myers Squibb by 1.1% in the 4th quarter. Thoroughbred Financial Services LLC now owns 17,763 shares of the biopharmaceutical company's stock worth $1,004,000 after acquiring an additional 190 shares during the period. Marcum Wealth LLC lifted its stake in shares of Bristol Myers Squibb by 1.0% in the 1st quarter. Marcum Wealth LLC now owns 19,296 shares of the biopharmaceutical company's stock worth $1,177,000 after acquiring an additional 193 shares during the period. Leelyn Smith LLC lifted its stake in shares of Bristol Myers Squibb by 0.5% in the 4th quarter. Leelyn Smith LLC now owns 47,699 shares of the biopharmaceutical company's stock worth $2,698,000 after acquiring an additional 215 shares during the period. Finally, Heron Bay Capital Management lifted its stake in shares of Bristol Myers Squibb by 2.1% in the 4th quarter. Heron Bay Capital Management now owns 10,795 shares of the biopharmaceutical company's stock worth $611,000 after acquiring an additional 220 shares during the period. Hedge funds and other institutional investors own 76.41% of the company's stock.

Bristol Myers Squibb Trading Up 0.7%

Shares of NYSE BMY traded up $0.32 during midday trading on Tuesday, reaching $46.81. 4,817,672 shares of the stock were exchanged, compared to its average volume of 12,842,630. The company has a market capitalization of $95.26 billion, a P/E ratio of 17.53, a P/E/G ratio of 1.39 and a beta of 0.36. Bristol Myers Squibb Company has a 52-week low of $39.50 and a 52-week high of $63.33. The company has a current ratio of 1.28, a quick ratio of 1.17 and a debt-to-equity ratio of 2.65. The stock has a 50 day moving average price of $47.69 and a 200-day moving average price of $53.50.

Bristol Myers Squibb (NYSE:BMY - Get Free Report) last issued its quarterly earnings results on Thursday, April 24th. The biopharmaceutical company reported $1.80 EPS for the quarter, topping analysts' consensus estimates of $1.50 by $0.30. The business had revenue of $11.20 billion during the quarter, compared to the consensus estimate of $10.77 billion. Bristol Myers Squibb had a net margin of 11.38% and a return on equity of 87.62%. The company's quarterly revenue was down 5.6% compared to the same quarter last year. During the same period in the previous year, the firm posted ($4.40) earnings per share. Equities research analysts expect that Bristol Myers Squibb Company will post 6.74 earnings per share for the current fiscal year.

Bristol Myers Squibb Announces Dividend

The business also recently announced a quarterly dividend, which will be paid on Friday, August 1st. Investors of record on Thursday, July 3rd will be given a $0.62 dividend. The ex-dividend date of this dividend is Thursday, July 3rd. This represents a $2.48 annualized dividend and a dividend yield of 5.30%. Bristol Myers Squibb's dividend payout ratio is presently 92.88%.

Insider Activity

In related news, EVP Samit Hirawat bought 4,250 shares of the firm's stock in a transaction that occurred on Friday, April 25th. The shares were acquired at an average cost of $47.58 per share, with a total value of $202,215.00. Following the completion of the transaction, the executive vice president owned 83,513 shares of the company's stock, valued at approximately $3,973,548.54. The trade was a 5.36% increase in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. Corporate insiders own 0.09% of the company's stock.

Wall Street Analyst Weigh In

Several analysts have recently commented on the stock. Cantor Fitzgerald restated a "neutral" rating and issued a $55.00 target price on shares of Bristol Myers Squibb in a research note on Tuesday, April 22nd. Argus upgraded shares of Bristol Myers Squibb to a "hold" rating in a report on Friday, April 25th. UBS Group cut their price target on shares of Bristol Myers Squibb from $60.00 to $54.00 and set a "neutral" rating for the company in a report on Friday, April 11th. Wall Street Zen downgraded shares of Bristol Myers Squibb from a "strong-buy" rating to a "buy" rating in a report on Friday, June 6th. Finally, The Goldman Sachs Group reiterated a "neutral" rating and issued a $55.00 price target (down previously from $67.00) on shares of Bristol Myers Squibb in a report on Tuesday, April 8th. Two investment analysts have rated the stock with a sell rating, thirteen have assigned a hold rating, six have assigned a buy rating and two have given a strong buy rating to the stock. According to MarketBeat.com, the stock currently has an average rating of "Hold" and a consensus price target of $58.00.

About Bristol Myers Squibb

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, and neuroscience diseases. The company's products include Eliquis for reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation, and for the treatment of DVT/PE; Opdivo for various anti-cancer indications, including bladder, blood, CRC, head and neck, RCC, HCC, lung, melanoma, MPM, stomach and esophageal cancer; Pomalyst/Imnovid for multiple myeloma; Orencia for active rheumatoid arthritis and psoriatic arthritis; and Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia.